Emend IV
(Fosaprepitant)ApprovedSmall molecule
Merck & Co.Fosaprepitant is used to prevent nausea and vomiting caused by chemotherapy treatment for cancer. It works by blocking signals in the brain that trigger these side effects.[2] Emend IV is currently approved and in use across 12 indications[4].[1]
Emend IV is one of 329 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Approved.
12
Indications
25
Total Trials
4
Active Trials
328
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Emend IV
Merck & Co.Approved
Prolia
AmgenPreclinical
Zolymbus
AbbViePreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Dextromethorphan Hydrobromide
Boehringer IngelheimPreclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chemotherapy-induced nausea and vomiting3 trials
Nausea and vomiting3 trials
PrEP2 trials
Dexamethasone2 trials
14 more indications
Prospective1 trial
Vomiting1 trial
Breast Cancer1 trial
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05841849·1,028 enrolled
Renal Cell Carcinoma1 trial
Nasopharyngeal Carcinoma1 trial
Multiple Myeloma1 trial
Brain Injury1 trial
Cervical Cancer1 trial
General Anesthesia1 trial
Advanced NSCLC1 trial
Thoracic Surgery1 trial
Carboplatin1 trial
Low Dose Aprepitant for Patients Receiving Carboplatin
Terminated·—·Phase 2·NCT03237611·15 enrolled
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Emend IV drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Fosaprepitant. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Neurokinin 1 Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company